This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by The Neuro-Oncology Working Group of the German Cancer Society Search for Related Content PubMed PubMed Citation Articles by The Neuro-Oncology Working Group of the German Cancer Society, Social Bookmarking                            What's this?

Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma

From the Neuro-Oncology Working Group of the German Cancer Society, Germany.

Address reprint requests to Michael Weller, MD, Department of Neurology, University of Tübingen, Medical School, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany; e-mail: michael.weller{at}uni-tuebingen.de.

Purpose: The role of chemotherapy in the primary treatment of malignant glioma remains controversial. The results from the German-Austrian Glioma trial (GAG, 1983 to 1988) demonstrated a survival benefit for chemotherapy using carmustine (BCNU) plus teniposide (VM26) over BCNU alone in addition to radiotherapy in patients with a Karnofsky performance score (KPS) more than 60. The Neuro-Oncology Working Group (NOA) of the German Cancer Society therefore compared the efficacy of nimustine (ACNU) plus VM26 and ACNU plus cytarabine (Ara-C) chemotherapy in addition to standard radiotherapy in patients with newly diagnosed malignant glioma.

Patients and Methods: From 1994 to 2000, 375 patients were randomly assigned to receive radiotherapy and cycles of ACNU 90 mg/m² intravenously (IV) on day 1 and VM26 60 mg/m² IV on days 1 to 3 (n = 183), or ACNU 90 mg/m² IV on day 1 and Ara-C 120 mg/m² IV on days 1 to 3 (n = 179), in 6-week intervals. Thirteen patients were not eligible after central neuropathology review. The remaining 362 patients had glioblastoma (n = 301) or anaplastic glioma (n = 61).

Results: Median survival and 2-year survival rates were 17.3 months and 25% for ACNU plus VM26, and 15.7 months and 29% for ACNU plus Ara-C in glioblastoma, and 60 months and 88% for ACNU plus VM26 and 62.5 months and 72% for ACNU plus Ara-C in anaplastic glioma. Multivariate analysis revealed no survival advantage for either arm or for subpopulations defined by histology, age, or KPS. Hematologic toxicity was more prominent in the ACNU plus Ara-C arm.

Conclusion: The median survival times and 2-year survival rates for patients with anaplastic glioma and glioblastoma achieved in the NOA-01 trial compare favorably with historical trials and with the Radiation Therapy Oncology Group database. The toxicity profile favors ACNU plus VM26 for further evaluation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Wick, J. Felsberg, J. P. Steinbach, U. Herrlinger, M. Platten, B. Blaschke, R. Meyermann, G. Reifenberger, M. Weller, and W. Wick Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma J. Clin. Oncol., August 1, 2007; 25(22): 3357 - 3361. [Abstract] [Full Text] [PDF]

				U. Herrlinger, J. Rieger, D. Koch, S. Loeser, B. Blaschke, R.-D. Kortmann, J. P. Steinbach, T. Hundsberger, W. Wick, R. Meyermann, et al. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03 J. Clin. Oncol., September 20, 2006; 24(27): 4412 - 4417. [Abstract] [Full Text] [PDF]

				F. Schmidt, J. Fischer, U. Herrlinger, K. Dietz, J. Dichgans, and M. Weller PCV chemotherapy for recurrent glioblastoma Neurology, February 28, 2006; 66(4): 587 - 589. [Abstract] [Full Text] [PDF]

				R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]

				J. P. Steinbach, H. -P. Blaicher, U. Herrlinger, W. Wick, T. Nagele, R. Meyermann, M. Tatagiba, M. Bamberg, J. Dichgans, H. -O. Karnath, et al. Surviving glioblastoma for more than 5 years: The patient's perspective Neurology, January 24, 2006; 66(2): 239 - 242. [Abstract] [Full Text] [PDF]

				S. E. Combs, C. Thilmann, L. Edler, J. Debus, and D. Schulz-Ertner Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single Institution J. Clin. Oncol., December 1, 2005; 23(34): 8863 - 8869. [Abstract] [Full Text] [PDF]